Loading patent…
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsAdrian Lee, Alison Nagle, Steffi Oesterreich
Estimating the term…
Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.
A method of treating a subject with a cancer comprising:
A method of treating a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor.
The method of claim 15, wherein the cancer comprises an invasive ductal breast carcinoma (IDC).
A method of increasing the sensitivity of a cancer in a subject to an IGF1 pathway inhibitor comprising administering to the subject a therapeutically effective amount of an E-cadherin inhibitor.
A method of detecting sensitivity of a cancer to IGF1R pathway inhibition in a subject comprising obtaining a cancerous tissue sample;
A pharmaceutical composition comprising an IGF1R pathway inhibitor and an E-cadherin inhibitor.
A pharmaceutical composition comprising an IGF1R pathway inhibitor and an endocrine therapeutic.
Dependencies are inferred from the claim text.